Alzheimer disease

[1]  M. Mintun,et al.  Donanemab in Early Alzheimer's Disease. , 2021, The New England journal of medicine.

[2]  David T. Jones,et al.  New insights into atypical Alzheimer's disease in the era of biomarkers , 2021, The Lancet Neurology.

[3]  Keith A. Johnson,et al.  Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease , 2021, JAMA neurology.

[4]  W. Jagust,et al.  Temporal Dynamics of β-Amyloid Accumulation in Aging and Alzheimer Disease , 2021, Neurology.

[5]  G. Petsko,et al.  Endosomal recycling reconciles the Alzheimer’s disease paradox , 2020, Science Translational Medicine.

[6]  Peter R. Martin,et al.  Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease. , 2020, Cerebral cortex.

[7]  M. Ewers,et al.  Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer’s disease , 2020, Science Advances.

[8]  J. Smiley,et al.  Endosomal Dysfunction Induced by Directly Overactivating Rab5 Recapitulates Prodromal and Neurodegenerative Features of Alzheimer's Disease. , 2020, Cell reports.

[9]  B. Dickerson,et al.  In It Together: A Qualitative Meta-Synthesis of Common and Unique Psychosocial Stressors and Adaptive Coping Strategies of Persons With Young-Onset Dementia and Their Caregivers. , 2020, The Gerontologist.

[10]  C. Haass,et al.  Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer’s Disease , 2020, Neuron.

[11]  H. Snyder,et al.  Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[12]  Ilene G. Ladd,et al.  D‐CARE: The Dementia Care Study: Design of a Pragmatic Trial of the Effectiveness and Cost Effectiveness of Health System–Based Versus Community‐Based Dementia Care Versus Usual Dementia Care , 2020, Journal of the American Geriatrics Society.

[13]  B. Hyman,et al.  Synergy between amyloid-β and tau in Alzheimer’s disease , 2020, Nature Neuroscience.

[14]  Naaheed Mukadam,et al.  Dementia prevention, intervention, and care: 2020 report of the Lancet Commission , 2020, The Lancet.

[15]  T. Spires-Jones,et al.  The physiological roles of tau and Aβ: implications for Alzheimer’s disease pathology and therapeutics , 2020, Acta Neuropathologica.

[16]  K. Blennow,et al.  Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. , 2020, JAMA.

[17]  Muhammad Naveed Iqbal Qureshi,et al.  18F-MK-6240 PET for early and late detection of neurofibrillary tangles. , 2020, Brain : a journal of neurology.

[18]  D. Dickson,et al.  Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40 , 2020, Alzheimer's Research & Therapy.

[19]  Derek H. Oakley,et al.  Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease , 2020, Nature Medicine.

[20]  F. Schmitt,et al.  Prevalence and Clinical Phenotype of Quadruple Misfolded Proteins in Older Adults. , 2020, JAMA neurology.

[21]  Terrance T. Kummer,et al.  Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. , 2020, The Journal of clinical investigation.

[22]  David T. Jones,et al.  Progressive dysexecutive syndrome due to Alzheimer’s disease: a description of 55 cases and comparison to other phenotypes , 2020, Brain communications.

[23]  R. Lipton,et al.  Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study , 2020, medRxiv.

[24]  P. Tariot,et al.  Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[25]  R. Nixon.  The aging lysosome: An essential catalyst for late-onset neurodegenerative diseases. , 2020, Biochimica et Biophysica Acta - Proteins and Proteomics.

[26]  S. Schicktanz,et al.  Addressing ethical challenges of disclosure in dementia prediction: limitations of current guidelines and suggestions to proceed , 2020, BMC medical ethics.

[27]  O. Hansson,et al.  Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders , 2020, JAMA neurology.

[28]  A. Boxer,et al.  Targeting tau: Clinical trials and novel therapeutic approaches , 2020, Neuroscience Letters.

[29]  K. Blennow,et al.  Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts , 2020, The Lancet Neurology.

[30]  T. Hortobágyi,et al.  An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders , 2020, Nature Reviews Neurology.

[31]  Philip S. Insel,et al.  The A4 study: β‐amyloid and cognition in 4432 cognitively unimpaired adults , 2020, Annals of clinical and translational neurology.

[32]  K. Ramasamy,et al.  Proteomics as a reliable approach for discovery of blood-based Alzheimer’s disease biomarkers: A systematic review and meta-analysis , 2020, Ageing Research Reviews.

[33]  H. Zetterberg,et al.  Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies , 2020, Molecular Psychiatry.

[34]  V. Gradinaru,et al.  LRP1 is a master regulator of tau uptake and spread , 2020, Nature.

[35]  Albert Hofman,et al.  Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study , 2020, Brain : a journal of neurology.

[36]  Nick C Fox,et al.  A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease , 2020, Nature Medicine.

[37]  Carrie D. Patnode,et al.  Screening for Cognitive Impairment in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. , 2020, JAMA.

[38]  K. Yaffe,et al.  Issues and Questions Surrounding Screening for Cognitive Impairment in Older Patients. , 2020, JAMA.

[39]  R. Nixon,et al.  β2-adrenergic agonists rescue lysosome acidification and function in PSEN1 deficiency by reversing defective ER to lysosome delivery of ClC-7. , 2020, Journal of molecular biology.

[40]  R. Brinton.  Faculty Opinions recommendation of Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins. , 2020 .

[41]  Alzheimer's Disease Neuroimaging Initiative.  Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease , 2020 .

[42]  D. Airey,et al.  Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease , 2020 .

[43]  Timothy J. Hohman,et al.  Dysregulation of multiple metabolic networks related to brain transmethylation and polyamine pathways in Alzheimer disease: A targeted metabolomic and transcriptomic study , 2020, PLoS medicine.

[44]  H. Nakanishi.  Microglial cathepsin B as a key driver of inflammatory brain diseases and brain aging , 2019, Neural regeneration research.

[45]  D. Na,et al.  [18F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment , 2019, Journal of clinical neurology.

[46]  R. Sperling,et al.  Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways , 2019, Nature Reviews Neurology.

[47]  L. Goldstein,et al.  Amyloid-β-independent regulators of tau pathology in Alzheimer disease , 2019, Nature Reviews Neuroscience.

[48]  James G. Bollinger,et al.  High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis , 2019, Neurology.

[49]  D. Holtzman,et al.  Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model , 2019, The Journal of experimental medicine.

[50]  N. Mizushima,et al.  Diverse Cellular Roles of Autophagy. , 2019, Annual review of cell and developmental biology.

[51]  J. Fak,et al.  A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP β-CTFs, Not Aβ , 2019, Neuron.

[52]  David T. Jones,et al.  The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes , 2019, Brain : a journal of neurology.

[53]  R. Petersen,et al.  Data from: Subjective cognitive decline and risk of MCI: the Mayo Clinic Study of Aging , 2019 .

[54]  David T. Jones,et al.  Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer’s Association Research Framework , 2019, JAMA neurology.

[55]  D. Wilton,et al.  Neuron-Glia Signaling in Synapse Elimination. , 2019, Annual review of neuroscience.

[56]  Virginia M. Y. Lee,et al.  TREM2 function impedes tau seeding in neuritic plaques , 2019, Nature Neuroscience.

[57]  David T. Jones,et al.  Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. , 2019, JAMA.

[58]  W. Annaert,et al.  Endo-lysosomal dysregulations and late-onset Alzheimer’s disease: impact of genetic risk factors , 2019, Molecular Neurodegeneration.

[59]  Keith A. Johnson,et al.  Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease , 2019, JAMA neurology.

[60]  D. Perani,et al.  Predicting long‐term clinical stability in amyloid‐positive subjects by FDG‐PET , 2019, Annals of clinical and translational neurology.

[61]  M. Carrillo,et al.  Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia , 2019, JAMA.

[62]  David T. Jones,et al.  Entorhinal cortex tau, amyloid-&bgr;, cortical thickness and memory performance in non-demented subjects , 2019, Brain : a journal of neurology.

[63]  M. Ikram,et al.  The incidence of mild cognitive impairment: A systematic review and data synthesis , 2019, Alzheimer's & dementia.

[64]  L. Goldstein,et al.  Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons , 2019, Cell stem cell.

[65]  Eden R Martin,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[66]  C. Haass,et al.  Secreted APP Modulates Synaptic Activity: A Novel Target for Therapeutic Intervention? , 2019, Neuron.

[67]  Nick C Fox,et al.  Polygenic risk and hazard scores for Alzheimer's disease prediction , 2019, Annals of clinical and translational neurology.

[68]  J. Williamson,et al.  Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial , 2019, JAMA.

[69]  P. Codogno,et al.  Autophagy Is Required for Memory Formation and Reverses Age-Related Memory Decline , 2019, Current Biology.

[70]  B. Miller,et al.  Alzheimer’s disease clinical variants show distinct regional patterns of neurofibrillary tangle accumulation , 2019, bioRxiv.

[71]  Theresa M. Harrison,et al.  Longitudinal tau accumulation and atrophy in aging and alzheimer disease , 2019, Annals of neurology.

[72]  I. Vertkin,et al.  Secreted amyloid-β precursor protein functions as a GABABR1a ligand to modulate synaptic transmission , 2019, Science.

[73]  G. Logroscino,et al.  A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease , 2019, Nature Reviews Neurology.

[74]  J. Molinuevo,et al.  Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid* , 2019, Molecular & Cellular Proteomics.

[75]  G. Kroemer,et al.  Biological Functions of Autophagy Genes: A Disease Perspective , 2019, Cell.

[76]  P. Mathews,et al.  Apolipoprotein E4 genotype compromises brain exosome production , 2018, Brain : a journal of neurology.

[77]  D. Holtzman,et al.  Amyloid-β and Tau at the Crossroads of Alzheimer's Disease. , 2019, Advances in experimental medicine and biology.

[78]  C. Jack,et al.  Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment , 2019, JAMA neurology.

[79]  I. Nelken,et al.  Tau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivo , 2018, Nature Neuroscience.

[80]  Douglas Galasko,et al.  Alzheimer's disease: The right drug, the right time , 2018, Science.

[81]  José Luis Molinuevo,et al.  Current state of Alzheimer’s fluid biomarkers , 2018, Acta Neuropathologica.

[82]  Maiken Nedergaard,et al.  The glymphatic pathway in neurological disorders , 2018, The Lancet Neurology.

[83]  Nick C Fox,et al.  Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia , 2018, Annals of neurology.

[84]  K. Blennow,et al.  Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[85]  B. Miller,et al.  Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders , 2018, JAMA.

[86]  Sean J. Miller,et al.  Tau Protein Disrupts Nucleocytoplasmic Transport in Alzheimer’s Disease , 2018, Neuron.

[87]  W. M. van der Flier,et al.  Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project , 2018, JAMA neurology.

[88]  D. Bennett,et al.  Deconstructing and targeting the genomic architecture of human neurodegeneration , 2018, Nature Neuroscience.

[89]  T. Dawson,et al.  Animal models of neurodegenerative diseases , 2018, Nature Neuroscience.

[90]  Cécile Proust-Lima,et al.  Association of Cardiovascular Health Level in Older Age With Cognitive Decline and Incident Dementia , 2018, JAMA.

[91]  R. Petersen.  How early can we diagnose Alzheimer disease (and is it sufficient)? , 2018, Neurology.

[92]  Brian A. Gordon,et al.  Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease , 2018, Neurology.

[93]  C. Jack,et al.  Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting , 2018, JAMA neurology.

[94]  E. Benarroch.  Glutamatergic synaptic plasticity and dysfunction in Alzheimer disease , 2018, Neurology.

[95]  John L. Robinson,et al.  Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated , 2018, Brain : a journal of neurology.

[96]  A. Klegeris,et al.  Emerging roles of microglial cathepsins in neurodegenerative disease , 2018, Brain Research Bulletin.

[97]  Albert Hofman,et al.  The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study , 2018, The Lancet Neurology.

[98]  Derek H. Oakley,et al.  Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain , 2018, Front. Neurosci..

[99]  David T. Jones,et al.  FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis , 2018, Brain : a journal of neurology.

[100]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[101]  J. Cummings,et al.  Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study , 2018, The Lancet Neurology.

[102]  J. Trojanowski,et al.  CSF biomarkers of Alzheimer’s disease concord with amyloid-β PETand predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts , 2018, Alzheimer's & Dementia.

[103]  C. Rowe,et al.  Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions , 2018, Nature Reviews Neurology.

[104]  J. Iliff,et al.  The Emerging Relationship Between Interstitial Fluid–Cerebrospinal Fluid Exchange, Amyloid-β, and Sleep , 2018, Biological Psychiatry.

[105]  T. Uchihara,et al.  Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB consortium , 2018, Neurology.

[106]  Ronald C. Petersen,et al.  Practice guideline update summary: Mild cognitive impairment , 2018, Neurology.

[107]  Lei Yu,et al.  Person‐specific contribution of neuropathologies to cognitive loss in old age , 2018, Annals of neurology.

[108]  K. Inokuchi,et al.  Autophagy Enhances Memory Erasure through Synaptic Destabilization , 2017, The Journal of Neuroscience.

[109]  Christopher G Schwarz,et al.  Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. , 2018, Brain : a journal of neurology.

[110]  Clifford R. Jack,et al.  Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum , 2017, Cortex.

[111]  J. Sepulcre,et al.  In vivo staging of regional amyloid deposition , 2017, Neurology.

[112]  Sonia M. Thomas,et al.  Comparisons of Interventions for Preventing Falls in Older Adults: A Systematic Review and Meta-analysis , 2017, JAMA.

[113]  R. Redon,et al.  Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls , 2017, Neurobiology of Aging.

[114]  G. Petsko,et al.  Endosomal Traffic Jams Represent a Pathogenic Hub and Therapeutic Target in Alzheimer’s Disease , 2017, Trends in Neurosciences.

[115]  Guy M. McKhann,et al.  Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort , 2017, JAMA neurology.

[116]  H. Niu,et al.  Prevalence and incidence of Alzheimer's disease in Europe: A meta-analysis. , 2017, Neurologia.

[117]  A. Fagan,et al.  ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy , 2017, Nature.

[118]  Wenli Hu,et al.  The significant effects of cerebral microbleeds on cognitive dysfunction: An updated meta-analysis , 2017, PloS one.

[119]  C. Wattmo,et al.  Early- versus late-onset Alzheimer’s disease in clinical practice: cognitive and global outcomes over 3 years , 2017, Alzheimer's Research & Therapy.

[120]  A. Konnerth,et al.  BACE inhibition-dependent repair of Alzheimer’s pathophysiology , 2017, Proceedings of the National Academy of Sciences.

[121]  Keith A. Johnson,et al.  Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex , 2017, JAMA neurology.

[122]  R. Nixon.  Amyloid precursor protein and endosomal‐lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[123]  Klaus P. Ebmeier,et al.  Trajectories of Depressive Symptoms Before Diagnosis of Dementia: A 28-Year Follow-up Study , 2017, JAMA psychiatry.

[124]  Monique M. B. Breteler,et al.  The changing prevalence and incidence of dementia over time — current evidence , 2017, Nature Reviews Neurology.

[125]  Rosemary J. Jackson,et al.  Tau association with synaptic vesicles causes presynaptic dysfunction , 2017, Nature Communications.

[126]  C. DeCarli,et al.  Impact of multiple pathologies on the threshold for clinically overt dementia , 2017, Acta Neuropathologica.

[127]  A. Rahmim,et al.  Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition , 2017, JAMA.

[128]  M. Korte,et al.  Not just amyloid: physiological functions of the amyloid precursor protein family , 2017, Nature Reviews Neuroscience.

[129]  Josiah R. Boivin,et al.  Soluble oligomeric amyloid-β induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain , 2017, Molecular Neurodegeneration.

[130]  S. P. Andrews,et al.  Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities , 2017, Neuron.

[131]  Nick C. Fox,et al.  Consensus classification of posterior cortical atrophy , 2017, Alzheimer's & Dementia.

[132]  J. Hopwood,et al.  Endo‐lysosomal and autophagic dysfunction: a driving factor in Alzheimer's disease? , 2017, Journal of neurochemistry.

[133]  D. Holtzman,et al.  Apolipoprotein E and Alzheimer’s disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins , 2017, Journal of Lipid Research.

[134]  M. Mintun,et al.  Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition , 2017, Brain : a journal of neurology.

[135]  H. Kim,et al.  Deficient autophagy in microglia impairs synaptic pruning and causes social behavioral defects , 2016, Molecular Psychiatry.

[136]  L. Hemmy,et al.  Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer’s-Type Dementia , 2017 .

[137]  X. Cagigas,et al.  Patient and caregiver goals for dementia care , 2017, Quality of Life Research.

[138]  L. Mucke,et al.  Network abnormalities and interneuron dysfunction in Alzheimer disease , 2016, Nature Reviews Neuroscience.

[139]  S. Ginsberg,et al.  Autophagy flux in CA1 neurons of Alzheimer hippocampus: Increased induction overburdens failing lysosomes to propel neuritic dystrophy , 2016, Autophagy.

[140]  David T. Jones,et al.  Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum , 2016, Neurobiology of Aging.

[141]  Edo Richard,et al.  Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial , 2016, The Lancet.

[142]  M. Prince,et al.  Recent global trends in the prevalence and incidence of dementia, and survival with dementia , 2016, Alzheimer's Research & Therapy.

[143]  Jarkko Johansson,et al.  Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study , 2016, Brain : a journal of neurology.

[144]  S. A. Hussaini,et al.  Neuronal activity enhances tau propagation and tau pathology in vivo , 2016, Nature Neuroscience.

[145]  Yi Su,et al.  Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease , 2016, Science Translational Medicine.

[146]  A. Fagan,et al.  Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. , 2016, JAMA neurology.

[147]  Daniel R. Schonhaut,et al.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[148]  W. Klein,et al.  Intraneuronal aggregation of the β-CTF fragment of APP (C99) induces Aβ-independent lysosomal-autophagic pathology , 2016, Acta Neuropathologica.

[149]  P. Trzepacz,et al.  Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia. , 2016, Psychosomatics.

[150]  J. Pantel,et al.  Neuroimaging of hippocampal atrophy in early recognition of Alzheimer´s disease – a critical appraisal after two decades of research , 2016, Psychiatry Research: Neuroimaging.

[151]  M. Schumacher,et al.  Incidence of Dementia over Three Decades in the Framingham Heart Study. , 2016, The New England journal of medicine.

[152]  H. Higashida,et al.  Neurotransmitter release: vacuolar ATPase V0 sector c-subunits in possible gene or cell therapies for Parkinson’s, Alzheimer’s, and psychiatric diseases , 2016, The Journal of Physiological Sciences.

[153]  B. Dubois,et al.  Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial , 2015, International Psychogeriatrics.

[154]  Rosemary J. Jackson,et al.  Post-mortem brain analyses of the Lothian Birth Cohort 1936: extending lifetime cognitive and brain phenotyping to the level of the synapse , 2015, Acta Neuropathologica Communications.

[155]  K. Blennow,et al.  Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. , 2015, Brain : a journal of neurology.

[156]  Frederik Barkhof,et al.  The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. , 2015, Brain : a journal of neurology.

[157]  R. Nixon,et al.  Presenilin 1 Maintains Lysosomal Ca(2+) Homeostasis via TRPML1 by Regulating vATPase-Mediated Lysosome Acidification. , 2015, Cell reports.

[158]  J. Williamson,et al.  Effect of a 24-Month Physical Activity Intervention vs Health Education on Cognitive Outcomes in Sedentary Older Adults: The LIFE Randomized Trial. , 2015, JAMA.

[159]  A. Tales,et al.  To revitalize neurology we need to address physician burnout , 2015, Neurology.

[160]  Lars Bäckman,et al.  A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial , 2015, The Lancet.

[161]  B. Hyman,et al.  APOEε2 is associated with milder clinical and pathological Alzheimer disease , 2015, Annals of neurology.

[162]  Karl Herrup,et al.  The case for rejecting the amyloid cascade hypothesis , 2015, Nature Neuroscience.

[163]  Matthew L Senjem,et al.  Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span. , 2015, JAMA neurology.

[164]  W. M. van der Flier,et al.  Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. , 2015, Brain : a journal of neurology.

[165]  N. Morel,et al.  The membrane domain of vacuolar H+ATPase: a crucial player in neurotransmitter exocytotic release , 2015, Cellular and Molecular Life Sciences.

[166]  Clifford R. Jack,et al.  Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum , 2015, Brain : a journal of neurology.

[167]  E. Stern,et al.  Pathological Tau Disrupts Ongoing Network Activity , 2015, Neuron.

[168]  David T. Jones,et al.  Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia , 2015, Neurobiology of Aging.

[169]  C. Jack,et al.  Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly , 2015, Brain : a journal of neurology.

[170]  Robert A. Koeppe,et al.  The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.

[171]  C. Kawas,et al.  Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques , 2014, Neurobiology of Disease.

[172]  Andrew J. Saykin,et al.  A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease , 2014, Alzheimer's & Dementia.

[173]  Janna H. Neltner,et al.  Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.

[174]  Teng Jiang,et al.  Microglia in Alzheimer's Disease , 2014, BioMed research international.

[175]  Dong-Hou Kim,et al.  Autophagy in microglia degrades extracellular β-amyloid fibrils and regulates the NLRP3 inflammasome , 2014, Autophagy.

[176]  A. Goate,et al.  Alzheimer’s Disease Genetics: From the Bench to the Clinic , 2014, Neuron.

[177]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[178]  Bradley T. Hyman,et al.  The Intersection of Amyloid Beta and Tau at Synapses in Alzheimer’s Disease , 2014, Neuron.

[179]  Cindee M. Madison,et al.  Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology , 2014, NeuroImage: Clinical.

[180]  D. Holtzman,et al.  Neuronal activity regulates extracellular tau in vivo , 2014, The Journal of experimental medicine.

[181]  W. Noble,et al.  A role for tau at the synapse in Alzheimer's disease pathogenesis , 2014, Neuropharmacology.

[182]  C. Bouras,et al.  Amyloid deposition is decreasing in aging brains , 2014, Neurology.

[183]  P. Vemuri,et al.  Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences , 2014, Clinical epidemiology.

[184]  M. Mintun,et al.  Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid , 2013, Annals of neurology.

[185]  David T. Jones,et al.  Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity , 2013, Neurology.

[186]  Toshiko Tanaka,et al.  Alzheimer's disease risk genes and the age-at-onset phenotype , 2013, Neurobiology of Aging.

[187]  K. Adams,et al.  The effectiveness of dyadic interventions for people with dementia and their caregivers , 2013, Dementia.

[188]  A. Fagan,et al.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study , 2013, The Lancet Neurology.

[189]  Shizuo Akira,et al.  Autophagy in infection, inflammation and immunity , 2013, Nature Reviews Immunology.

[190]  C. Jack,et al.  Mild cognitive impairment due to Alzheimer disease in the community , 2013, Annals of neurology.

[191]  R. Nixon,et al.  The role of autophagy in neurodegenerative disease , 2013, Nature Medicine.

[192]  G. Alexander,et al.  Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. , 2013, JAMA neurology.

[193]  Cindee M. Madison,et al.  Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. , 2013, Brain : a journal of neurology.

[194]  Keith A. Johnson,et al.  Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association , 2013, The Journal of Nuclear Medicine.

[195]  Y. Stern.  Cognitive reserve in ageing and Alzheimer's disease , 2012, The Lancet Neurology.

[196]  Reisa A. Sperling,et al.  Subjective cognitive complaints and amyloid burden in cognitively normal older individuals , 2012, Neuropsychologia.

[197]  R. Nixon,et al.  Autophagy and neuronal cell death in neurological disorders. , 2012, Cold Spring Harbor perspectives in biology.

[198]  G. Frisoni,et al.  Resting state fMRI in Alzheimer's disease: beyond the default mode network , 2012, Neurobiology of Aging.

[199]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[200]  Ole A. Andreassen,et al.  A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline , 2012, Nature.

[201]  M. Copetti,et al.  Neuropsychiatric symptoms and functional status in Alzheimer's disease and vascular dementia patients. , 2012, Current Alzheimer research.

[202]  M. Leissring,et al.  Proteolytic degradation of amyloid β-protein. , 2012, Cold Spring Harbor perspectives in medicine.

[203]  H. Soininen,et al.  CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings , 2012, Neurology.

[204]  C. Haass,et al.  Trafficking and proteolytic processing of APP. , 2012, Cold Spring Harbor perspectives in medicine.

[205]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[206]  Naruhiko Sahara,et al.  Propagation of Tau Pathology in a Model of Early Alzheimer's Disease , 2012, Neuron.

[207]  Menno P. Witter,et al.  Trans-Synaptic Spread of Tau Pathology In Vivo , 2012, PloS one.

[208]  Dietmar R. Thal,et al.  Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.

[209]  R. Petersen,et al.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.

[210]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[211]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[212]  Ralph A. Nixon,et al.  Autophagy failure in Alzheimer's disease—locating the primary defect , 2011, Neurobiology of Disease.

[213]  C. DeCarli,et al.  Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline , 2011, Alzheimer's & Dementia.

[214]  O. El Far,et al.  A role for V‐ATPase subunits in synaptic vesicle fusion? , 2011, Journal of neurochemistry.

[215]  P. Scheltens,et al.  The World of Dementia Beyond 2020 , 2011, Journal of the American Geriatrics Society.

[216]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[217]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[218]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[219]  Richard J. Kryscio,et al.  Alzheimer’s disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies , 2011, Acta Neuropathologica.

[220]  J. Morris,et al.  Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.

[221]  Carole Dufouil,et al.  Longitudinal neuroimaging correlates of subjective memory impairment: 4-year prospective community study. , 2011, The British journal of psychiatry : the journal of mental science.

[222]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[223]  M. Albert,et al.  Introduction to Revised Criteria for the Diagnosis of Alzheimer ’ s Disease : National Institute on Aging and the Alzheimer Association Workgroups , 2011 .

[224]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[225]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup , 2011 .

[226]  E G Tangalos,et al.  Prevalence of mild cognitive impairment is higher in men , 2010, Neurology.

[227]  Christopher Kircher.  COGNITIVE DECLINE IN INCIDENT ALZHEIMER DISEASE IN A COMMUNITY POPULATION , 2010, Neurology.

[228]  R. Petersen,et al.  Mayo Clinic Study of Aging , 2010, Alzheimer's & Dementia.

[229]  Du Feng,et al.  Membrane localization of beta-amyloid 1-42 in lysosomes: a possible mechanism for lysosome labilization. , 2010, The Journal of biological chemistry.

[230]  George Perry,et al.  Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. , 2010, Biochimica et biophysica acta.

[231]  Seiji Nishino,et al.  Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle , 2009, Science.

[232]  S. Leurgans,et al.  The neuropathology of probable Alzheimer disease and mild cognitive impairment , 2009, Annals of neurology.

[233]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[234]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[235]  G. Alexander,et al.  Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[236]  Keith A. Johnson,et al.  Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease , 2009, The Journal of Neuroscience.

[237]  A. Nógrádi,et al.  Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. , 2009, Brain : a journal of neurology.

[238]  Scott A. Small,et al.  Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis , 2008, Neuron.

[239]  E. Koo,et al.  Amyloid Precursor Protein Trafficking, Processing, and Function* , 2008, Journal of Biological Chemistry.

[240]  B. Miller,et al.  The logopenic/phonological variant of primary progressive aphasia , 2008, Neurology.

[241]  Arthur Konnerth,et al.  Clusters of Hyperactive Neurons Near Amyloid Plaques in a Mouse Model of Alzheimer's Disease , 2008, Science.

[242]  Brian J. Bacskai,et al.  Aβ Plaques Lead to Aberrant Regulation of Calcium Homeostasis In Vivo Resulting in Structural and Functional Disruption of Neuronal Networks , 2008, Neuron.

[243]  D. Schacter,et al.  The Brain's Default Network , 2008, Annals of the New York Academy of Sciences.

[244]  B. L. Beattie,et al.  Disclosure of the diagnosis of dementia , 2007, Alzheimer's & Dementia.

[245]  H. Hampel,et al.  No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. , 2007, Brain : a journal of neurology.

[246]  E. Todeva.  Networks , 2007 .

[247]  F. Jessen,et al.  Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho‐Tau in patients with low‐ and high‐CSF Aβ40 load , 2007 .

[248]  Henrik Zetterberg,et al.  Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment , 2007, Dementia and Geriatric Cognitive Disorders.

[249]  Bin Zhang,et al.  Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model , 2007, Neuron.

[250]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[251]  Nick C Fox,et al.  Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study , 2006, The Lancet Neurology.

[252]  Steven Mennerick,et al.  Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo , 2005, Neuron.

[253]  P. T. Nguyen,et al.  Dendritic Spine Abnormalities in Amyloid Precursor Protein Transgenic Mice Demonstrated by Gene Transfer and Intravital Multiphoton Microscopy , 2005, The Journal of Neuroscience.

[254]  R. Petersen.  Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[255]  M. Greicius,et al.  Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI , 2004, Proc. Natl. Acad. Sci. USA.

[256]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[257]  E. Masliah,et al.  Immunoelectron microscopic study of synaptic pathology in Alzheimer's disease , 2004, Acta Neuropathologica.

[258]  A. M. Clarfield,et al.  The decreasing prevalence of reversible dementias: an updated meta-analysis. , 2003, Archives of internal medicine.

[259]  D. Davies,et al.  Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes , 2003, Neurobiology of Disease.

[260]  Florence Pasquier,et al.  Tau aggregation in the hippocampal formation: an ageing or a pathological process? , 2002, Experimental Gerontology.

[261]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[262]  R. Mohs,et al.  A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients , 2001, Neurology.

[263]  H. Stanley,et al.  Plaque‐Induced Abnormalities in Neurite Geometry in Transgenic Models of Alzheimer Disease: Implications for Neural System Disruption , 2001, Journal of neuropathology and experimental neurology.

[264]  B T Hyman,et al.  Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. , 2000, The American journal of pathology.

[265]  A. Delacourte,et al.  The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease , 1999, Neurology.

[266]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[267]  E B Larson,et al.  Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. , 1998, Neurology.

[268]  B. Hyman,et al.  LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted β-amyloid precursor protein and mediates its degradation , 1995, Cell.

[269]  B. Hyman,et al.  Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions , 1993, Neuron.

[270]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[271]  G. V. Van Hoesen,et al.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.

[272]  S. DeKosky,et al.  Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity , 1990, Annals of neurology.

[273]  G. V. Van Hoesen,et al.  Reinnervation of the hippocampal perforant pathway zone in Alzheimer's disease , 1987, Annals of neurology.

[274]  S. DeKosky,et al.  Reactive synaptogenesis in hippocampal area CA1 of aged and young adult rats , 1986, The Journal of comparative neurology.

[275]  C. Cotman,et al.  Plasticity in hippocampal excitatory amino acid receptors in Alzheimer's disease , 1986, Neuroscience Research.